Full-Time
Global healthcare company manufacturing medical devices
$113.3k - $226.7k/yr
Chicago, IL, USA
In Person
On-site at Willis Tower, Chicago, IL; occasional travel 5%.
Bachelor's
See people who can refer or advise you
Abbott develops and sells medical technologies and health solutions across cardiovascular care, diabetes management, diagnostics, nutrition, and neuromodulation. Cardiovascular devices help manage heart health; diabetes products enable glucose monitoring; diagnostic tests provide timely results; nutrition products support health; neuromodulation therapies target the nervous system to relieve pain or aid movement. It differentiates itself with a broad, integrated portfolio and a focus on accessibility and affordability of technologies worldwide. Its goal is to improve global health and well-being by delivering life-changing technologies that are accessible and affordable.
Company Size
10,001+
Company Stage
IPO
Headquarters
Lake Bluff, Illinois
Founded
1888
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Professional Development Budget
Wellness Program
Abbott to pay $851.6 million to settle some preterm infant formula cases. Abbott did not admit liability in the Aug 20 settlement, saying it remains confident in the safety of its infant formula products. Published Aug 21, 2026, 08:42 AM Updated Aug 21, 2026, 08:42 AM * Abbott agreed to a US$670 million settlement to partly resolve lawsuits alleging harm from its preterm infant formulas, including a US$495 million judgment upheld in 2026. * The lawsuits involve about 2,000 claimants, with up to 12,700 claims including duplicates and cases against Abbott and Mead Johnson for necrotising enterocolitis. * Abbott denies liability, citing confidence in product safety; the disease mainly affects premature infants and is linked to lack of breast milk rather than formula use according to experts. AI generated NEW YORK - Abbott said on Aug 20 that it reached a $670 million (S$851.6 million) settlement to partially resolve the ongoing litigation over alleged harms linked to its specialty formulas for preterm infants. The settlement was agreed to by three law firms representing about 2,000 people with claims against Abbott, including one Illinois mother who won a US$495 million judgment in 2024 after a jury concluded that Abbott's formula caused her daughter to develop necrotising enterocolitis, a dangerous bowel disease. Abbott agreed to drop its efforts to appeal that verdict, which had been upheld by a Missouri appeals court in May 2026. Abbott did not admit liability in the Aug 20 settlement, saying it remains confident in the safety of its infant formula products. The company said in a statement that the deal is a step towards "substantially resolving the overall litigation". Abbott, which makes Similac formulas, said about 1,700 lawsuits have been filed against it and Mead Johnson, a unit of Reckitt, which manufactures Enfamil formulas. Some of the lawsuits name both companies as defendants and some are filed on behalf of multiple plaintiffs.
Asset Advisors Investment Management LLC reduces stock holdings in Abbott Laboratories $ABT. August 21, 2026 Asset Advisors Investment Management LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 55.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,495 shares of the healthcare product maker's stock after selling 61,557 shares during the period. Asset Advisors Investment Management LLC's holdings in Abbott Laboratories were worth $4,400,000 as of its most recent filing with the Securities and Exchange Commission. Several other hedge funds have also recently made changes to their positions in the company. Freemont Management S.A. grew its holdings in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock valued at $1,341,000 after buying an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth about $116,580,000. Thrivent Financial for Lutherans boosted its position in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock valued at $30,931,000 after acquiring an additional 48,286 shares during the period. Aureus Asset Management LLC grew its stake in Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock valued at $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Finally, Concurrent Investment Advisors LLC increased its holdings in Abbott Laboratories by 23.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker's stock worth $11,124,000 after acquiring an additional 17,137 shares during the period. 75.18% of the stock is currently owned by institutional investors. Abbott Laboratories news summary. Here are the key news stories impacting Abbott Laboratories this week: * Positive Sentiment: Abbott's Instinct continuous glucose sensor is now integrated into MiniMed's Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott's presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor * Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott * Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott's cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott's Medical Devices Growth Catalyst * Neutral Sentiment: Recent commentary remains broadly constructive on Abbott's long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends. * Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement * Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict Abbott Laboratories stock performance. NYSE ABT opened at $114.16 on Friday. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a fifty day moving average of $99.51 and a 200-day moving average of $99.93. The company has a market capitalization of $197.54 billion, a P/E ratio of 36.94, a P/E/G ratio of 2.21 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. The firm's revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year. Abbott Laboratories dividend announcement. The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%. Analysts set new price targets. Several analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. Bank of America decreased their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, July 17th. TD Cowen restated a "buy" rating and set a $115.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, UBS Group decreased their target price on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $118.67. Abbott Laboratories profile. Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions. In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Abbott Laboratories, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list. While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Genomics testing lab notifies nearly 310,000 of hack. Baylor Genetics Among the Latest Medical Labs, Bio-Tech Firms Attacked Marianne Kolbasuk McGee (HealthInfoSec) - August 20, 2026 Genomics testing firm Baylor Genetics is notifying nearly 310,000 people and counting about a June hack that compromised sensitive patient information including test results and employee data. The incident is the latest in a rash of attacks hitting medical laboratories, biotech and life sciences firms. Baylor Genetics has so far reported to several state attorneys general that nearly 250,000 Texans were affected, as well as nearly 57,000 citizens in Massachusetts and more than 2,600 residents of Vermont. Baylor Genetics in a breach notice said that it discovered suspicious activity on a limited portion of its IT environment around June 15. An investigation into the incident determined that a threat actor accessed portions of Baylor Genetics' network and certain stored data between June 11 and June 17. Patient information potentially compromised varied by individual but may have included names, date of birth, medical testing information, laboratory test results, health insurance information, as well as Social Security number for a limited subset of individuals. For current or former employees, the information potentially affected may have included personal identifying information such as Social Security numbers, government-issued identification numbers and financial account information. "At this time, Baylor Genetics is not aware of any confirmed identity theft, fraud or misuse of personal information related to this incident," the company said. No cybercrime groups have surfaced on the darkweb claiming responsibility for the incident. As its name implies, Baylor Genetics provides genetic testing and diagnostic services, including genomic sequencing, to uncover conditions related to rare diseases, pediatric genetics, reproductive health, hereditary cancer, metabolic disorders and other issues. The company's roots trace to 1978 when two physician-scientists founded the department of molecular and human genetics at Baylor College of Medicine. By 1996, the company was selected as one of six pilot sites for the final phases of the Human Genome Project, a research endeavor that has led to modern-day genomics discoveries. Baylor Genetics did not immediately respond to ISMG's request for additional details pertaining to its hacking incident. The Baylor Genetics breach report comes on the heels of hacks on other medical laboratories, bio tech companies and med tech firms in recent weeks and months. Similar breaches. Other recent hacks include the theft of data from clinical testing laboratory and medical device maker Abbott Laboratories and its cancer diagnostics business Exact Sciences. Cybercrime gang ShinyHunters and another gang, ShadowByt3$, each claimed to steal data - including artificial intelligence models - from Abbott's Exact Sciences unit (see: Craneware, Abbott Probe Separate Health Data Theft Incidents). Also, cybercrime gang FulcrumSec in recent weeks claimed it leaked on its darkweb site two large caches of data the group claims it stole in a June attack on Novo Nordisk. The latest data dump allegedly includes the Danish drug maker's "complete enterprise Hugging Face AI and machine learning ecosystem" (see: Extortion Gang Leaks Novo Nordisk 'AI and ML Ecosystem'). In addition to FulcrumSec's claims, in June, a second hacker group, TheUSERS007, told Databreaches.net that it also stole "crown jewel" data - including AI models - from the maker of popular diabetes and weight loss treatment drugs Ozempic and Wegovy. While healthcare sector entities have long been targeted by hackers, life sciences, medical testing and biotech companies and other such sectors are especially attractive targets for cybercriminals, some experts said. "These organizations hold an unusually valuable combination of sensitive health information, personally identifiable information and, in some cases, proprietary research and intellectual property," said Dave Bailey, vice president of solutions and strategy at healthcare privacy and security consultancy Clearwater. "Genomic information is especially sensitive because, unlike a password or credit card number, it is inherently permanent. You cannot change your DNA after a breach." There could be several reasons for the apparent recent focus by cybercriminals on life- and bio-science firms, said Mike Hamilton, CISO emeritus at IT services firm Datec, Inc. "First, they are regulated as a covered entity, and unauthorized disclosure of records brings regulatory action. Additionally, they house sensitive privacy and health information, and our privacy laws facilitate class action when those records are stolen," he said. "Both of those facts give criminals substantial leverage when negotiating extortion demands." Hamilton said it's unlikely that the kind of genetic testing information potentially stolen in the Baylor Genetics hack or similar incidents will be monetized by selling it on the darkweb, "although it may be interesting to some nation states that routinely steal research from American companies." Apart from the threat of regulatory action and civil litigation, hackers also pose additional risk to the integrity of the information compromised, he said. "If it can be stolen, it can be changed. This puts the victim organizations in an even worse position, unable to trust the veracity of their own data - which could have life-safety impacts," he said. "Again, this gives the criminal organization a great deal of leverage." Organizations such as life sciences, medical labs and biotech companies should identify their most sensitive data and systems and apply protections commensurate with the consequences if those assets are compromised, Bailey said. "That means strong segmentation, least-privilege access, phishing-resistant multifactor authentication, encryption, rigorous third-party access controls and continuous monitoring for unusual access or data movement." Meanwhile, AI in the hands of hackers raises the stakes for these companies because it enables attackers to create more convincing phishing and social-engineering campaigns and operate at greater speed and scale, he said. "Organizations should increasingly assume that credentials may eventually be compromised and build controls that prevent one compromised identity from becoming unrestricted access to sensitive data," he said. "Just as importantly, they should regularly test their ability to detect, contain and recover from an attack rather than relying solely on preventative controls."
Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.
Medtech breaches keep hitting corporate IT, not devices - and that's a blind spot in hospital vendor risk. Abbott, Stryker, Intuitive, Medtronic and other medtech companies disclosed cyberattacks this year. None involved a device - and the pattern should reshape how hospitals assess vendor risk. By Carrie Pallardy Aug 17, 2026, 3:22 PM Seven medical technology companies disclosed cyberattacks in the first half of 2026, and not one involved a compromised device. Instead, attackers are opting for corporate IT - internal applications, billing systems, customer portals and, in one case, a third-party platform sitting two steps away from any hospital. "The Hollywood version of medical device cybersecurity is hacking the pacemaker, but the everyday reality is hacking the company that makes the pacemaker," said Daniel Bardenstein, CEO and co-founder of Manifest Cyber and Aspen Policy Academy fellow. And the pace is picking up. Health care providers remain a popular target, but attacks on health care businesses - pharmaceutical companies, billing companies and health care technology providers - jumped 35% in the first half of this year compared to the second half of 2025, according to Comparitech. Stryker, Abbott, Intuitive, Medtronic, UFP Technologies and iRhythm have all disclosed attacks this year, according to company statements. Nearly every disclosure carried the same reassurance - no products were impacted - which is true as far as it goes, but the systems attackers did reach are the ones that hold hospital and patient data and keep billing, orders and deliveries moving. Why medtech companies. Like other parts of the health care supply chain, medtech companies safeguard valuable data and provide services the industry can't operate without, which makes them attractive to financially motivated groups. One of the groups claiming an Abbott attack was ShinyHunters - and the cybersecurity information sharing nonprofit Health-ISAC recently warned that ShinyHunters is having increased success targeting medical technology companies, according to BleepingComputer. Jamie Singer, a senior managing director at FTI Consulting, told DHI that most attacks she has observed on medtech companies have some element of data access and extortion. "They're [attackers] trying to get paid, and when they don't, then they make it very miserable for the organization," she said. "Not all have the disruptive nature, but most that we're seeing certainly have the data theft piece." For other threat actors, disruption is the goal rather than a byproduct. "When you're talking about nation state actors, I do think there is a goal of disruption to critical infrastructure in the US," Singer said. The Handala claim on the Stryker attack fits that pattern. What it costs hospitals. Medtech companies sit inside a tightly interconnected health care ecosystem, and the impact of an attack rarely stays inside the company's walls. "If a hospital gets breached through a medical device or otherwise, not only do those medical devices not work but the whole system may not work," said Sean Kelly, MD, chief medical officer at Imprivata, a digital identity security company, and a practicing ER physician. Kelly has received patients diverted from hospitals disrupted by cyberattacks. "When that happens, patients arrive and you don't have access to their data," he said. "We're starting over trying to understand what their meds are, what their problems are, how to treat them." The result, according to Kelly: care delays, higher risk of errors and increased costs. Regulation mirrors the blind spot. Regulators have taken steps, though largely on the side of the equation attackers are avoiding. The FDA's premarket cybersecurity requirements focus on the device itself, while HHS's Cybersecurity Performance Goals for the health care and public health sector, released in 2024, remain voluntary. "There has been work [done] to identify: how do we establish a minimum, and how do we do the basics better across the sector?" Bardenstein said. "I think there needs to be an increase in what is mandatory and not what is aspirational." "It means that despite the millions of dollars that security leaders at the medtech companies are currently spending, the tooling or the processes they have aren't enough," he added. For hospitals, the same question applies to their own side of the relationship. Most vendor risk assessments still focus on the device - whether it's patched, segmented and hardened against attack. This year's attacks point somewhere else entirely: to the security of the company that makes the pacemaker. Carrie Pallardy, a Chicago-based freelance writer and editor, began her career covering healthcare more than a decade ago. Her work has taken into many different industries, but covering healthcare delivery remains a constant focus. She can be reached at [email protected] or on LinkedIn. Show your support. Subscribe. Enter your information below